• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by BiondVax Pharmaceuticals Ltd.

    1/4/23 9:21:26 AM ET
    $BVXV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BVXV alert in real time by email
    SC 13G 1 bvxv0123.txt SABBY 13G BVXV 1.04.23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* BiondVax Pharmaceuticals Ltd. (Name of Issuer) ADSs (Title of Class of Securities) 09073Q105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ? CUSIP No. 09073Q105 1. NAME OF REPORTING PERSONS Sabby Volatility Warrant Master Fund, Ltd. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 228,329 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 228,329 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 228,329 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO? CUSIP No. 09073Q105 1. NAME OF REPORTING PERSONS Sabby Management, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 228,329 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 228,329 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 228,329 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO CUSIP No. 09073Q105 1. NAME OF REPORTING PERSONS Hal Mintz 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 228,329 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 228,329 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 228,329 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN? CUSIP No. 09073Q105 Item 1. (a). Name of Issuer: BiondVax Pharmaceuticals Ltd. (b). Address of issuer's principal executive offices: Jerusalem BioPark, Second Floor Hadassah Ein Kerem Campus Jerusalem, L3 00000 Item 2. (a). Name of person filing: Sabby Volatility Warrant Master Fund, Ltd. Sabby Management, LLC Hal Mintz (b). Address or principal business office or, if none, residence: Sabby Volatility Warrant Master Fund, Ltd. c/o Ogier Fiduciary Services (Cayman) Limited 89 Nexus Way, Camana Bay Grand Cayman KY1-9007 Cayman Islands Sabby Management, LLC 115 Hidden Hills Dr. Spicewood, TX 78669 Hal Mintz c/o Sabby Management, LLC 115 Hidden Hills Dr. Spicewood, TX 78669 (c). Citizenship: Sabby Volatility Warrant Master Fund, Ltd. - Cayman Islands Sabby Management, LLC - Delaware, USA Hal Mintz - USA (d). Title of class of securities: ADSs (the ADSs) (e). CUSIP No.: 09073Q105 Item 3. If This Statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [_] An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [_] A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) [_] Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: Sabby Volatility Warrant Master Fund, Ltd. - 228,329 Sabby Management, LLC - 228,329 Hal Mintz - 228,329 (b) Percent of class: Sabby Volatility Warrant Master Fund, Ltd. - 9.99% Sabby Management, LLC - 9.99% Hal Mintz - 9.99% ( (c) Number of shares as to which the person has: Sabby Volatility Warrant Master Fund, Ltd. ( (i) Sole power to vote or to direct the vote 0 , ( (ii) Shared power to vote or to direct the vote 228,329 , ( (iii) Sole power to dispose or to direct the disposition of 0 , ( (iv) Shared power to dispose or to direct the disposition of 228,329 . Sabby Management, LLC (i) Sole power to vote or to direct the vote 0 , ( (ii) Shared power to vote or to direct the vote 228,329 , ( (iii) Sole power to dispose or to direct the disposition of 0 , ( (iv) Shared power to dispose or to direct the disposition of 228,329 . Hal Mintz ( (i) Sole power to vote or to direct the vote 0 , ( (ii) Shared power to vote or to direct the vote 228,329 , ( (iii) Sole power to dispose or to direct the disposition of 0 , ( (iv) Shared power to dispose or to direct the disposition of 228,329 . As calculated in accordance with Rule 13d-3 of the Securities Exchange Act of 1934, as amended, (i) Sabby Volatility Warrant Master Fund, Ltd. beneficially owns 228,329 shares of the Issuer's ADSs (ADSs), representing approximately 9.99% of the ADSs, and (ii) Sabby Management, LLC and Hal Mintz each beneficially own 228,329 shares of the ADSs, representing approximately 9.99% of the ADSs. Sabby Management, LLC and Hal Mintz do not directly own any shares of ADSs, but each indirectly owns 228,329 shares of ADSs. Sabby Management, LLC, a Delaware limited liability company, indirectly owns 228,329 shares of ADSs because it serves as the investment manager of Sabby Volatility Warrant Master Fund, Ltd. Mr. Mintz indirectly owns 228,329 shares of ADSs in his capacity as manager of Sabby Management, LLC. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following []. ? Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of Group. Not applicable ? Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. ? SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. January 4, 2023 (Date) Sabby Volatility Warrant Master Fund, Ltd. By: /s/ Harry Thompson Name: Harry Thompson Title: Authorized Person of TDF Management Ltd., a Director Sabby Management, LLC* By: /s/ Robert Grundstein Name: Robert Grundstein Title: Chief Operating Officer /s/ Hal Mintz* Hal Mintz *This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein. The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent. Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). EXHIBIT 1 ---------- JOINT FILING AGREEMENT The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of ADSs of BiondVax Pharmaceuticals Ltd.is filed jointly, on behalf of each of them. Dated: January 4, 2023 Sabby Volatility Warrant Master Fund, Ltd. By: /s/ Harry Thompson Name: Harry Thompson Title: Authorized Person of TDF Management Ltd., a Director Sabby Management, LLC By: /s/ Robert Grundstein Name: Robert Grundstein Title: Chief Operating Officer /s/ Hal Mintz Hal Mintz
    Get the next $BVXV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BVXV

    DatePrice TargetRatingAnalyst
    1/26/2022$7.00Buy
    Aegis Capital
    More analyst ratings

    $BVXV
    SEC Filings

    See more
    • SEC Form EFFECT filed by BiondVax Pharmaceuticals Ltd.

      EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      2/14/24 12:15:33 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form F-3 filed by BiondVax Pharmaceuticals Ltd.

      F-3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      1/30/24 4:19:12 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by BiondVax Pharmaceuticals Ltd.

      6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      1/18/24 11:50:50 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Margolin Yael claimed ownership of 66,800 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:16:22 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Laster Morris C claimed ownership of 66,800 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:10:29 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Lowell George claimed ownership of 421,680 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:04:49 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

      JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. ("Scinai"). In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new corporate name, which was approved by the Israeli authorities on August 31, is the Company's latest step to better reflect its fresh start and new direction. Scinai and its new symbol, "SCNI", will debut on Nasdaq tomorro

      9/6/23 6:00:00 AM ET
      $APGE
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiondVax Reports Second Quarter Financial Results and Provides Business Update

      JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update. Second Quarter 2023 Financial Summary R&D expenses for the three months ended June 30, 2023, amounted to $1.45 million compared with $1.97 million for the three months ended June 30, 2022.Marketing, general and administrative expenses for the three months ended June 30, 2

      8/11/23 9:00:00 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

      JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax's multi-faceted plan to regain compliance with Nasdaq's Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance. As previously disclosed, BiondVax received a deficiency letter dated May 1, 2023, from Nasdaq notifying the Company that it is not in compliance with the minimum stockholders' equity requirement for con

      8/1/23 4:01:00 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Leadership Updates

    Live Leadership Updates

    See more
    • BiondVax Announces Third Quarter 2020 Financial Results & Business Update

      JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its third quarter financial results for the quarter ended September 30, 2020. Third Quarter 2020 Financial Summary Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.441 (NIS/$US) as at September 30, 2020. Total operating income for the third quarter was NIS 55.6 million (approximately $16.1 million) compared with a total operating loss of NI

      1/28/21 3:23:00 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiondVax Announces Appointment of Amir Reichman as New CEO

      JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment of infectious diseases, today announced the appointment of Amir Reichman as its new CEO. Mr. Reichman and Ron Babecoff, BiondVax's founder and current CEO, will share duties during a transition period while Mr. Reichman completes his work obligations at GlaxoSmithKline (GSK), a global pharmaceutical company. Effective March 2, 2021, Mr. Reichman will assume the CEO position full time and Mr. Babecoff will continue as Senior Advisor to the Company. Continue Reading BiondVa

      1/21/21 7:15:00 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BiondVax Pharmaceuticals Ltd.

      SC 13G - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      2/14/24 3:53:32 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BiondVax Pharmaceuticals Ltd. (Amendment)

      SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      1/24/24 2:33:59 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BiondVax Pharmaceuticals Ltd. (Amendment)

      SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      1/2/24 4:54:14 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital initiated coverage on BiondVax Pharmaceuticals with a new price target

      Aegis Capital initiated coverage of BiondVax Pharmaceuticals with a rating of Buy and set a new price target of $7.00

      1/26/22 10:21:55 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care